| Overview |
| bs-0924R-FITC |
| Mafa Polyclonal Antibody, FITC Conjugated |
| WB, IF(IHC-P) |
| Human, Mouse, Rat |
| Specifications |
| FITC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human Mafa |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 389692 |
| Nucleus |
| Mafa homolog; V-maf musculoaponeurotic fibrosarcoma oncogene homolog A;Pancreatic beta-cell-specic transcriptional activator;avianV-maf musculoaponeurotic fibrosarcoma oncogene homolog A; MAFA_MOUSE. |
| Insulin gene expression is regulated by several islet-enriched transcription factors. However, MAFA is the only beta cell-specific activator. MAFA selectively induces endogenous insulin transcription in non-beta cells. MAFA was also first detected in the insulin-producing cells formed during the second and predominant phase of beta cell differentiation, and absent in the few insulin-positive cells found in Nkx6.1(-/-) pancreata, which lack the majority of second-phase beta cells. These results demonstrate that MAFA is a potent insulin activator that is likely to function downstream of Nkx6.1 during islet insulin-producing cell development. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
Powered by Bioz